Table of Contents
ISRN Hepatology
Volume 2013, Article ID 130384, 5 pages
http://dx.doi.org/10.1155/2013/130384
Research Article

Absence of Hepatitis B Resistance Mutants before Introduction of Oral Antiviral Therapy

1Section of Gastroenterology & Hepatology, Department of Internal Medicine, School of Medicine, Tulane University, 1430 Tulane Avenue, SL-35, New Orleans, LA 70112, USA
2Center for Liver Diseases, University of Miami, School of Medicine, 1500 NW 12th Avenue, Suite 1101, Miami, FL 33136, USA

Received 6 July 2013; Accepted 13 August 2013

Academic Editors: C. Domenicotti, Z.-Z. Lin, and D. Morioka

Copyright © 2013 Martin Moehlen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction. The aim of this study was to assess whether hepatitis B virus drug resistant mutations antedated the widespread use of nucleos(t)ide analogues in treatment naïve patients. A number of reports have suggested that drug resistant mutants can be detected in apparently treatment naïve patients. Study. Fifty deidentified serum samples collected from 1986 to 1992 from patients with replicative chronic HBV infection at the University of Miami were genotyped and tested for resistance mutations using a line probe assay InnoLiPA HBV DR v2/v3. Serum HBV DNA was measured. All patients had documented chronic HBV infection with a detectable viral load, HBeAg seropositivity, and absence of HIV infection. Results. Of the 50 individuals included, 86% were male, mean age was 40 ± 12 years, and mostly genotype A. The mean HBV DNA was 126 pg/mL (range 6.4 to 557.0). No mutations were identified. Conclusions. The absence of drug induced mutations in these sera collected several years prior to the introduction of oral antiviral therapy suggests that these mutations do not occur in treatment naïve populations. Detection of drug resistance in an apparently treatment naïve subject suggests either unrecognized prior antiviral therapy or infection by an inoculum from a treatment experienced patient.